Keyphrases
Doxorubicin
100%
Canine
100%
Tolerability
100%
Nave
100%
Multicentric Lymphoma
100%
Complete Response
42%
Self-limiting
28%
Lymphoma
28%
Guanine
14%
Prodrug
14%
Financial Resources
14%
Mechanism of Action
14%
Clinical Significance
14%
Gastrointestinal
14%
Nucleoside Analogues
14%
Pulmonary Fibrosis
14%
Progression-free Interval
14%
Multi-agent
14%
Adverse Events
14%
Partial Response
14%
Agent Behavior
14%
Combination Chemotherapy
14%
Overall Response Rate
14%
Hematologic
14%
Remission
14%
Time Resources
14%
Treatment Standards
14%
Prospective Clinical Trial
14%
Agent Interaction Protocols
14%
Previously Untreated
14%
Chemotherapy Combinations
14%
Adverse Effect Profile
14%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
100%
Tolerability
100%
Rabacfosadine
100%
Chemotherapy
28%
Adverse Event
28%
Clinical Trial
14%
Prodrug
14%
Guanine
14%
Lung Fibrosis
14%
Progression Free Survival
14%
Dermatological Agent
14%
Remission
14%
Veterinary Science and Veterinary Medicine
Canine
100%
Dog
100%
Doxorubicin
100%